# A Study of Monthly Intravenous C.E.R.A. (Mircera) in Hemodialysis Participants With Chronic Renal Anemia

> **NCT00699348** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 351 (actual)

## Conditions studied

- Anemia

## Interventions

- **DRUG:** Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)

## Key facts

- **NCT ID:** NCT00699348
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 351 (ACTUAL)
- **Last updated:** 2016-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00699348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00699348, "A Study of Monthly Intravenous C.E.R.A. (Mircera) in Hemodialysis Participants With Chronic Renal Anemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00699348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*